Navigation Links
FDA Approves New HIV Drug, Viread

Biopharmaceutical firm Gilead Sciences Inc. said it has received approval from the US Food and Drug Administration (FDA) to market its antiretroviral agent Viread (tenofovir disoproxil fumarate) for the treatment of HIV in combination with other antiretroviral agents.

Like Viread, such drugs work by blocking the process needed for HIV replication in the body. But Viread is the first nucleotide analogue reverse transcriptase inhibitor to be approved for treatment of HIV in the US. As a result//, it may offer a treatment option for patients whose infections have become resistant to currently available medications.

Foster City, California-based Gilead said that the 300 milligram tablet should be available within a few days. The company added that the once-a-day drug would be indicated for use in combination with other antiretroviral agents for the treatment of previously diagnosed patients.

In clinical trials, Viread reduced the level of circulating HIV by about 75%. The most common side effects included nausea, diarrhea, vomiting and flatulence. The drug has demonstrated a significant antiviral response, even in patients who may no longer respond well to available therapies due to the development of viral resistance.


'"/>




Page: 1

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves Birth Control Skin Patch
3. FDA Approves New Arthritis Drug, Bextra
4. FDA Approves Elidel Cream for Eczema
5. FDA Approves New Anti-Clotting Drug
6. FDA Approves New surgery Treatment for Farsightedness
7. FDA Approves Anti-Cancer Cell Drug - Zevalin
8. FDA Approves Remodulin for Pulmonary Hypertension
9. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: